- Current report filing (8-K)
June 16 2011 - 6:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): June 15, 2011
Impax Laboratories,
Inc.
(Exact name of registrant as
specified in its charter)
|
|
|
|
|
Delaware
|
|
001-34263
|
|
65-0403311
|
(State or other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
30831 Huntwood Avenue,
Hayward, CA
|
|
94544
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code:
(510) 476-2000
|
Not
Applicable
|
(Former name or former address if changed since last report.)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment
of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 15, 2011,
Charles V. Hildenbrand, Senior Vice President, Operations, informed Impax
Laboratories, Inc. (the “Company”) of his intent to resign
effective June 17, 2011. The Company is currently aggressively seeking a
new executive with experience in pharmaceutical manufacturing and operations.
On an interim basis, Mr. Hildenbrand’s responsibilities will be
assumed by the Chief Executive Officer of the Company.
1
2
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
Dated: June 16, 2011
IMPAX LABORATORIES, INC
.
By:
/s/ Arthur A.
Koch,
Jr.
Name:
Arthur A. Koch, Jr.
Title: Executive Vice President, Finance, and
Chief
Financial Officer
2
3
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From Jul 2024 to Jul 2024
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From Jul 2023 to Jul 2024